Fresenius, a listed global, therapy-focused healthcare company, has reduced its stake in Fresenius Medical Care (FME), a global provider of products and services for people with chronic kidney failure, to 25% through the sale of 7.8 million shares – approximately 2.9% of Fresenius Medical Care’s issued share capital. Through the sale of shares to institutional investors, Fresenius is raising approximately €300m (US$350m).
In March 2025, Fresenius raised approximately €1.1bn through a combined offering of shares in an accelerated bookbuilding and bonds exchangeable into FME shares maturing in 2028, reducing its shareholding from 32.2% to approximately 28.6%. In August 2025, FME initiated a series of share buyback programmes alongside which Fresenius sold shares on a pro rata basis, to approximately maintain its stake.
Net proceeds from this latest transaction will reduce group net debt and be available for future investment.
“With this step, we reduce our financial investment in Fresenius Medical Care and create additional flexibility to redeploy capital into our growth platforms,” said Michael Sen, CEO of Fresenius.
FME’s share price opened at €40.89 on the day of the announcement. They are quoted today at €40.35.
